These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 11070454)

  • 21. Novel albuterol multidose dry powder inhaler in patients with exercise-induced bronchoconstriction: A single-dose, double-blind, randomized, 2-way crossover study.
    Ostrom NK; Taveras H; Iverson H; Pearlman DS
    Respir Med; 2015 Nov; 109(11):1410-5. PubMed ID: 26475054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of exercise-induced bronchospasm in pediatric asthma patients: A comparison of two salmeterol powder delivery devices.
    Bronsky EA; Pearlman DS; Pobiner BF; Scott C; Wang Y; Stahl E
    Pediatrics; 1999 Sep; 104(3 Pt 1):501-6. PubMed ID: 10469776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients.
    Singh D; Piccinno A; Borrill Z; Poli G; Acerbi D; Meuleners L; Woodcock A
    Pulm Pharmacol Ther; 2008; 21(3):551-7. PubMed ID: 18321744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinically equivalent bronchodilatation achieved with formoterol delivered via Easyhaler and Aerolizer.
    Dubakiene R; Nargela R; Sakalauskas R; Vahteristo M; Silvasti M; Lähelmä S
    Respiration; 2006; 73(4):441-8. PubMed ID: 16432294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolonged protection against methacholine-induced bronchoconstriction by the inhaled beta 2-agonist formoterol.
    Ramsdale EH; Otis J; Kline PA; Gontovnick LS; Hargreave FE; O'Byrne PM
    Am Rev Respir Dis; 1991 May; 143(5 Pt 1):998-1001. PubMed ID: 1673830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of formoterol inhalation on endurance performance in hypobaric conditions.
    Riiser A; Tjørhom A; Carlsen KH
    Med Sci Sports Exerc; 2006 Dec; 38(12):2132-7. PubMed ID: 17146320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
    Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
    Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.
    Bjermer L; Rosenborg J; Bengtsson T; Lötvall J
    Ther Adv Respir Dis; 2013 Oct; 7(5):264-71. PubMed ID: 23907810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protection against cold air and exercise-induced bronchoconstriction while on regular treatment with Oxis.
    Vilsvik J; Ankerst J; Palmqvist M; Persson G; Schaanning J; Schwabe G; Johansson A
    Respir Med; 2001 Jun; 95(6):484-90. PubMed ID: 11421506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The duration of action of inhaled formoterol dry powder.
    Quebe-Fehling E; Brambilla R; Bromly CL; Fishwick K; Walters EH; Hendrick DJ
    Br J Clin Pract; 1996 Dec; 50(8):446-9. PubMed ID: 9039716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Actions other than smooth muscle relaxation may play a role in the protective effects of formoterol on the allergen-induced late asthmatic reaction.
    Brusasco V; Crimi E; Gherson G; Nardelli R; Oldani V; Francucci B; Della Cioppa G; Senn S; Fabbri LM
    Pulm Pharmacol Ther; 2002; 15(4):399-406. PubMed ID: 12220946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer.
    Lecaillon JB; Kaiser G; Palmisano M; Morgan J; Della Cioppa G
    Eur J Clin Pharmacol; 1999 Apr; 55(2):131-8. PubMed ID: 10335908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action.
    Celik G; Kayacan O; Beder S; Durmaz G
    Respiration; 1999; 66(5):434-9. PubMed ID: 10516540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol.
    Aziz I; Tan KS; Hall IP; Devlin MM; Lipworth BJ
    Eur Respir J; 1998 Sep; 12(3):580-4. PubMed ID: 9762783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 3-month comparison of formoterol with terbutaline via turbuhaler. A placebo-controlled study.
    Ekström T; Ringdal N; Tukiainen P; Runnerström E; Soliman S
    Ann Allergy Asthma Immunol; 1998 Sep; 81(3):225-30. PubMed ID: 9759798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
    Nelson HS; Gross NJ; Levine B; Kerwin EM; Rinehart M; Denis-Mize K;
    Clin Ther; 2007 Oct; 29(10):2167-78. PubMed ID: 18042473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
    Dahl R; Chung KF; Buhl R; Magnussen H; Nonikov V; Jack D; Bleasdale P; Owen R; Higgins M; Kramer B;
    Thorax; 2010 Jun; 65(6):473-9. PubMed ID: 20522841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients.
    Rosenborg J; Larsson P; Rott Z; Böcskei C; Poczi M; Juhász G
    Eur J Clin Pharmacol; 2002 Jul; 58(4):S61-7. PubMed ID: 12214580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction.
    Malo JL; Cartier A; Trudeau C; Ghezzo H; Gontovnick L
    Am Rev Respir Dis; 1990 Nov; 142(5):1147-52. PubMed ID: 1978619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylaxis of exercise-induced asthma with inhaled formoterol, a long-acting beta 2-adrenergic agonist.
    McAlpine LG; Thomson NC
    Respir Med; 1990 Jul; 84(4):293-5. PubMed ID: 2236756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.